reports
NYLI MacKay DefinedTerm Muni Opportunities Fund: 1 director
A director at NYLI MacKay DefinedTerm Muni Opportunities Fund sold 11,965 shares at 14.840USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recen...
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 µg) and Differentiated Safety and Tolerability Profile Entered Into Clinical Trial Collaboration and Supply Agreement With Pfizer to Evaluate Cemsidomide ...
Sensient Technologies Corp: 1 director
A director at Sensient Technologies Corp bought 2,150 shares at 92.980USD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offerin...
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering $125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab Potential to Earn up to an Additional $225 Million in Proceeds WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the pricing o...
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend SOUTHAMPTON, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (OTCQB: QNTO) (the "Company"), the holding company for Quaint Oak Bank, announced today that its Board of Directors declared a quarterly cash dividend of $0.04 per share on the common stock of the Company on October 8, 2025. The dividend is payable on November 3, 2025, to the shareholders of record at the close of business on October 20, 2025. Quaint Oak Bancorp, Inc., a Financial Services Company, is the parent company for the Quaint Oak Family of Compan...
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agre...
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO®), a B-cell m...
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Sup...
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population Responses Across Dose Levels With Median Duration of Response of 9.3 Months as of the Data Cut-off Date; Median Duration of Response Not Yet Reached at Two Highest Doses No Discontinuations ...
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA). BIIB142 is a degrader of IRAK4 that Biogen intends to explore for therapeuti...
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide ...
C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting C4T to Host Webcast on September 20, 2025 at 3 pm ET WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (...
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Rece...
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level Productive Type C Meeting Held With FDA; Registrational Development of Cemsidomide in Multiple Myeloma on Track to Initiate in Early 2026 Preclinical Milestone Achieved Under the Collaboration With Merck KGaA, Darmstadt, Germany, Which ...
QUAINT OAK BANCORP, INC. ANNOUNCES SECOND QUARTER EARNINGS
QUAINT OAK BANCORP, INC. ANNOUNCES SECOND QUARTER EARNINGS Southampton, PA , July 31, 2025 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (the “Company”) (OTCQB: QNTO), the holding company for Quaint Oak Bank (the “Bank”), announced today net income for the quarter ended June 30, 2025 of $272,000, or $0.10 per basic and diluted share, compared to net income of $100,000, or $0.04 per basic and diluted share, for the same period in 2024. Net income for the six months ended June 30, 2025 was $189,000, or $0.07 per basic and diluted share, compared to net income of $973,000, or $0.39 per basic ...
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend SOUTHAMPTON, Pa., July 11, 2025 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (OTCQB: QNTO) (the “Company”), the holding company for Quaint Oak Bank, announced today that its Board of Directors declared a quarterly cash dividend of $0.04 per share on the common stock of the Company on July 9, 2025. The dividend is payable on August 4, 2025, to the shareholders of record at the close of business on July 21, 2025. Robert T. Strong, Chief Executive Officer of the Company stated, “After careful consideration, the Board decided to reduce...
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recen...
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease Negative Complete Response; 40% ORR Achieved at the 75 µg Dose Level Cemsidomide Multiple Myeloma Dose Escalation is Complete; FDA Feedback Expected by Mid-Year 2025 to Support Initiation of Next Phase of Development in Early 2026 ...
Quaint Oak Bancorp, Inc. Announces First Quarter Earnings
Quaint Oak Bancorp, Inc. Announces First Quarter Earnings Southampton, PA , May 01, 2025 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (the “Company”) (OTCQB: QNTO), the holding company for Quaint Oak Bank (the “Bank”), announced today net loss for the quarter ended March 31, 2025 of $83,000, or $(0.03) per basic and diluted share, compared to net income of $873,000, or $0.36 per basic and diluted share, for the same period in 2024. Robert T. Strong, Chief Executive Officer stated, “First quarter results historically are not the best of our calendar year. Our first quarter results of this...
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend SOUTHAMPTON, Pa., April 10, 2025 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (OTCQB: QNTO) (the "Company"), the holding company for Quaint Oak Bank, announced today that its Board of Directors declared a quarterly cash dividend of $0.13 per share on the common stock of the Company on April 9, 2025. The dividend is payable on May 5, 2025, to the shareholders of record at the close of business on April 21, 2025. Quaint Oak Bancorp, Inc., a Financial Services Company, is the parent company for the Quaint Oak Family of Companies. Qua...
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Re...
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million as of December 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Feb. 27, 2025 (GLOBE N...
C4 Therapeutics to Participate in Upcoming March Investor Conferences
C4 Therapeutics to Participate in Upcoming March Investor Conferences WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences. TD Cowen 45th Annual Healthcare Conference: Management will present on March 3rd at 9:10 am ET in Boston, MA. The live webcast will be available on the of the company’s website. The archived replay of the webcast will be avail...
QUAINT OAK BANCORP, INC. ANNOUNCES FOURTH QUARTER AND YEAR-END EARNING...
QUAINT OAK BANCORP, INC. ANNOUNCES FOURTH QUARTER AND YEAR-END EARNINGS Southampton, PA , Jan. 31, 2025 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (the “Company”) (OTCQB: QNTO), the holding company for Quaint Oak Bank (the “Bank”), announced today net income for the quarter ended December 31, 2024 of $1.6 million, or $0.60 per basic and diluted share, compared to net income of $1.1 million, or $0.49 per basic and diluted share, for the same period in 2023. Net income for the year ended December 31, 2024 was $2.8 million, or $1.08 per basic and diluted share, compared to net income of $2...
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend SOUTHAMPTON, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (OTCQB: QNTO) (the "Company"), the holding company for Quaint Oak Bank, announced today that its Board of Directors declared a quarterly cash dividend of $0.13 per share on the common stock of the Company on January 15, 2025. The dividend is payable on February 10, 2025, to the shareholders of record at the close of business on January 27, 2025. Quaint Oak Bancorp, Inc., a Financial Services Company, is the parent company for the Quaint Oak Family of Comp...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols bymarket-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
WHR WHIRLPOOL CORPORATION
SLAB SILICON LABORATORIES INC.
LAKE LAKELAND INDUSTRIES INC.
GTE GRAN TIERRA ENERGY
DXPE DXP ENTERPRISES INC.
COG CABOT OIL & GAS CORPORATION
AXGN AXOGEN INC.
ALLT ALLOT LTD
MEG. MEG ENERGY CORP.
PARR PAR PACIFIC HOLDINGS INC
VFC V.F. CORPORATION
CDZI CADIZ INC.
IRTC IRHYTHM TECHNOLOGIES INC.
DK DELEK US HOLDINGS INC
SWTX SPRINGWORKS THERAPEUTICS
PGNY PROGYNY
CRMD CORMEDIX INC.
LPI LAREDO PETROLEUM INC.
FNMA FEDERAL NATIONAL MORTGAGE ASSOCIATION
OVV OVINTIV INC
PTLO PORTILLOS INC
CIVI CIVITAS RESOURCES INC
ARHS ARHAUS INC
OPFI OPPFI INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
SN SHARKNINJA INC
ARPL ARLA PLAST AB
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.